Board ‘Stripped,’ ‘Ignored’ Key Limitation In Patent Claims, Owner Says
WASHINGTON, D.C. — A pharmaceutical company is disputing findings by the Patent Trial and Appeal Board (PTAB or board) that its patented form of polymorphic fingolimod hydrochloride is anticipated by prior...To view the full article, register now.
Already a subscriber? Click here to view full article